



Leiden University  
Medical Center

# GCIG updates – PORTEC-3 and PORTEC-4a

Chicago, June 2-3, 2016




Carien Creutzberg

Leiden University Medical Centre, The Netherlands



# The PORTEC-3 trial

## ➤ High risk Endometrial Cancer



GYNECOLOGIC  
CANCER INTERGROUP  
An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

# PORTEC-3 trial – toxicity and quality of life




Presented at ASCO 2015; accepted to Lancet Oncology

## PORTEC-3 – progress and analysis


- Radiotherapy QA to be completed this year
- Ongoing data checks, queries, FU information and QOL
- ANZGOG: patient preferences substudy submitted  
TROG benchmarking short report submitted
- Analysis of pathology review in preparation (NL-UK)
- TransPORTEC consortium for translational research
- **Final analysis of PORTEC-3 expected 2017**
  - *depending on timely follow-up information and prompt reporting of events!*

# Molecular characteristics of endometrial cancer





# Molecular analysis PORTEC-1 and 2 cohort (N=834)

The 4 TCGA subgroups by surrogate markers in PORTEC-1/2




# Molecular integrated risk profile PORTEC-1/2 cohort



# Molecular integrated risk profile PORTEC-1/2 cohort


N=834



- Molecular integrated risk profile is a stronger risk stratification model with improved risk prediction
- Decrease overtreatment and undertreatment


# New PORTEC-4a trial design

- Molecular integrated vs standard indications for adjuvant treatment:




# New PORTEC-4a trial design

- Molecular integrated vs standard indications for adjuvant treatment:




# PORTEC-4a - started June 1<sup>st</sup> 2016

- Pilot phase: N = 50 (Netherlands)
    - *Endpoints: logistics, patient acceptance*
  - Proceed into full trial (international)
    - *Endpoints: vaginal recurrence, recurrence-free survival, AE and QOL, health costs*
  - Validation of molecular profile procedure in pathology centers -  
  > 3-4 in NL and in participating countries
  - NCRI UK and ANZGOG planning to participate
- *Interested in participation? Please contact us!*



# Thanks to all ---



# Thank you

ATTEC - 3  
International Intergroup Trial

